X

Drug Profile

Research programme: urological disorder therapeutics - IXALTIS

Latest Information Update: 04 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sanofi-Synthelabo
Developer IXALTIS
Class
Mechanism of Action Monoamine oxidase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Genitourinary disorders

Most Recent Events

04 Sep 2023 IXA-002 and IXA-003 are still in preclinical studies for Genitourinary disorders in France (IXALTIS pipeline, September 2023)
06 Jun 2016 IXALTIS in-licenses IXA 002 and IXA 003 from Sanofi
06 Jun 2016 Preclinical trials in Genitourinary disorders in France before June 2016 (IXALTIS pipeline, June 2016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com